Generics Bulletin Explains: One Year On, US Humira Biosimilars Continue To Struggle For Share
After 12 Months Of US Competition, Uptake Remains Low For Adalimumab Biosimilars
A year to the day since the launch of the first US rival to Humira, adalimumab biosimilars are still struggling to gain a significant foothold in the market. Generics Bulletin looks at the reasons why.
